US Patent

US8962629 — Tricyclic compounds

Method of Use · Assigned to AbbVie Inc · Expires 2031-01-15 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a class of tricyclic compounds useful for treating immunological and oncological conditions.

USPTO Abstract

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3371 — Rinvoq
U-3624 — Rinvoq
U-3624 — Rinvoq
U-3946 — Rinvoq

Patent Metadata

Patent number
US8962629
Jurisdiction
US
Classification
Method of Use
Expires
2031-01-15
Drug substance claim
Yes
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.